In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Over...

Disgrifiad llawn

Manylion Llyfryddiaeth

Cyhoeddwyd yn:	Antimicrob Agents Chemother
Prif Awduron:	Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Jones, R. N.
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	American Society for Microbiology (ASM) 2000
Pynciau:	Susceptibility
Mynediad Ar-lein:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90171/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10991880/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.10.2883-2886.2000
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!